14.91

3.54% 0.51

After Hours: 14.91

Celcuity Inc (CELC)

Overview News Price History Option Chain Financials Discussions Forecast

Celcuity Inc stock is traded at $14.91, with a volume of 186.27K. It is up +3.54% in the last 24 hours and down -6.58% over the past month. Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Previous Close:

$14.40

Open:

$14.37

24h Volume:

186.27K

Relative Volume:

0.59

Market Cap:

$536.20M

Revenue:

Net Income/Loss:

$-63.78M

P/E Ratio:

-5.6264

EPS:

-2.65

Net Cash Flow:

$-53.91M

1W Performance:

+6.65%

1M Performance:

-6.58%

6M Performance:

-30.97%

1Y Performance:

+63.13%

1-Day Range:

$14.26

$14.95

1-Week Range:

$13.86

$14.95

52-Week Range:

$8.389

$22.19

Celcuity Inc Stock (CELC) Company Profile

Name

Celcuity Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

763-392-0767

Address

16305 36TH AVENUE N, MINNEAPOLIS, MN

Employee

Twitter

Next Earnings Date

2024-08-14

Latest SEC Filings

CELC's Discussions on Twitter

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-24	Initiated	Leerink Partners	Outperform
Feb-22-24	Initiated	Stifel	Buy
Dec-08-23	Initiated	H.C. Wainwright	Buy
Oct-08-21	Initiated	Canaccord Genuity	Buy
Sep-07-21	Initiated	Jefferies	Buy
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy
Jan-28-21	Reiterated	H.C. Wainwright	Buy
Dec-24-20	Reiterated	H.C. Wainwright	Buy
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy

View All

Celcuity Inc Stock (CELC) Latest News

05:34 AM

Driehaus Capital Management LLC Has $3.35 Million Stake in Celcuity Inc. (NASDAQ:CELC) - MarketBeat

05:34 AM

Sep 29, 2024

Celcuity Inc. (NASDAQ:CELC) Short Interest Up 11.4% in September - MarketBeat

Sep 29, 2024

Sep 28, 2024

Blue Owl Capital Holdings LP Takes $1.07 Million Position in Celcuity Inc. (NASDAQ:CELC) - MarketBeat

Sep 28, 2024

Sep 24, 2024

Samlyn Capital LLC Purchases 637,190 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World

Sep 24, 2024

Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Sep 11, 2024

Celcuity Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Sep 11, 2024

Sep 10, 2024

Celcuity (CELC) Holds a Potential Game-changer in Cancer Treatment - Nasdaq

Sep 10, 2024

Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance

Sep 10, 2024

Sep 02, 2024

How To Trade (CELC) - Stock Traders Daily

Sep 02, 2024

Ready to Jump After Recent Trade: Celcuity Inc (CELC) - SETE News

Sep 02, 2024

Aug 31, 2024

Is Celcuity (NASDAQ:CELC) Using Too Much Debt? - Simply Wall St

Aug 31, 2024

Aug 28, 2024

Celcuity director sells shares worth $5,932 By Investing.com - Investing.com Australia

Aug 28, 2024

Celcuity director sells shares worth $5,932 - Investing.com India

Aug 28, 2024

Aug 27, 2024

Celcuity director sells shares worth $5,932 By Investing.com - Investing.com UK

Aug 27, 2024

Aug 26, 2024

Celcuity (NASDAQ:CELC) Coverage Initiated by Analysts at Lifesci Capital - MarketBeat

Aug 26, 2024

Celcuity (NASDAQ:CELC) Now Covered by Lifesci Capital - Defense World

Aug 26, 2024

Wall Street analysts’ outlook for Celcuity Inc (CELC) - SETE News

Aug 26, 2024

LifeSci Capital Initiates Coverage of Celcuity (CELC) with Outperform Recommendation - MSN

Aug 26, 2024

Aug 23, 2024